Controversias sobre el tratamiento con IECA/ARA-II y COVID-19

Arcos, Federico Soria; Puche, Antonio Romero; Vera, Tomás Vicente

doi:10.1016/j.recesp.2020.03.014

Cited by 9 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Concerns and doubts about their use on COVID-19 patients arise from animal studies suggesting that ARBs and ACEIs could increase the expression of ACE2 in the CV and renal systems [45][46][47]. Hence the doubt that an increase in ACE2 expression could aggravate the SARS-CoV-2 infection, due to a greater probability of entering the host cell and, consequently, the severity of COVID-19 in hypertensive and CVD patients who take these medications [48,49]. However, we have to emphasize that it is not yet known and even in animal models, whether overexpression of ACE2 actually facilitates greater engagement and entry of SARS-CoV, SARS-CoV-2 or other viruses.…”

Section: Interactions Of Sars-cov-2 With Ace2: the Debate About The Use Of Ras Inhibitors Is Dissolvingmentioning

confidence: 99%

COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?

Turco

Vianello

Ragusa

et al. 2020

Thrombosis Research

View full text Add to dashboard Cite

A Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) has become a pandemic disease named Coronavirus Disease-19 (COVID-19) of epochal dimension. The clinical spectrum of COVID-19 is wide, ranging from asymptomatic forms to severe pneumonia, sepsis and multiple organ dysfunction syndromes resulting in poor outcomes. Among the various consequences of severe COVID-19, cardiovascular (CV) collapse appears the most serious and potentially lethal. On the other hand, pre-existent CV comorbidities are also associated with higher mortality. The most reliable hypothetical pathogenetic mechanism for CV complications and cardiac injury in severe COVID-19 patients appears to be a sustained endothelial dysfunction, caused by the interplay of inflammation and coagulation. In this review, we survey papers addressing issues related to severe COVID-19, characterized by enhanced lung microvascular loss, hypercytokinemia, hypoxemia and thrombosis. We discuss about how the virus-induced downregulation of the angiotensin converting enzyme-2 (ACE2) receptor, used to enter the host cell, could affect the renin-angiotensin system, attempting to clarify the doubts about the use of ACE inhibitors and Angiotensin-II receptor blockers in COVID-19 patients. Finally, we point out how the delicate and physiological homeostatic function of the endothelium, which turns into a disastrous battlefield of the complex interaction between “cytokine and coagulative storms”, can be irreparably compromised and result in systemic inflammatory complications.

show abstract

Section: Interactions Of Sars-cov-2 With Ace2: the Debate About The Use Of Ras Inhibitors Is Dissolvingmentioning

confidence: 99%

COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?

Turco

Vianello

Ragusa

et al. 2020

Thrombosis Research

View full text Add to dashboard Cite

show abstract

“…No obstante, hasta la fecha, no hay una base suficiente para retirar estos tratamientos a los pacientes que ya los está n tomando. Como ya se ha comunicado en la Revista, las complicaciones de su retirada indiscriminada podrían superar a sus teó ricos efectos adversos 5 .…”

unclassified

Tratamiento de pacientes de cardio-onco-hematología durante la pandemia actual de COVID-19

Lorca

Triviño

Morı́s

2020

Revista Española de Cardiología

View full text Add to dashboard Cite

Integrating heterogeneous data to facilitate COVID-19 drug repurposing

Santamaría

Uzquiano

Carro

et al. 2022

Drug Discovery Today

View full text Add to dashboard Cite

In the COVID-19 pandemic, drug repositioning has presented itself as an alternative to the time-consuming process of generating new drugs. This review describes a drug repurposing process that is based on a new data-driven approach: we put forward five information paths that associate COVID-19-related genes and COVID-19 symptoms with drugs that directly target these gene products, that target the symptoms or that treat diseases that are symptomatically or genetically similar to COVID-19. The intersection of the five information paths results in a list of 13 drugs that we suggest as potential candidates against COVID-19. In addition, we have found information in published studies and in clinical trials that support the therapeutic potential of the drugs in our final list.

show abstract

Controversias sobre el tratamiento con IECA/ARA-II y COVID-19

Cited by 9 publications

References 4 publications

COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?

COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?

Tratamiento de pacientes de cardio-onco-hematología durante la pandemia actual de COVID-19

Integrating heterogeneous data to facilitate COVID-19 drug repurposing

Contact Info

Product

Resources

About